



Novel anti(lymph)angiogenic treatment strategies for corneal and ocular surface diseases

Felix Bock^{a,1}, Kazuichi Maruyama^{b,1}, Birgit Regenfuss^{a,1}, Deniz Hos^{a,1}, Philipp Steven^{a,1}, Ludwig M. Heindl^{a,1}, Claus Cursiefen^{a,*,1}

^a Department of Ophthalmology, University of Cologne, Cologne, Germany

^b Department of Ophthalmology, Tohoku University Graduate School of Medicine, Sendai, Japan

ARTICLE INFO

Article history:

Available online 22 January 2013

Keywords:

Lymphangiogenesis
Cornea
Therapeutic concepts
Angiogenesis
Inflammation
Melanoma
Two-photon
Dry eye
Keratoplasty
Genetic diversity
Macrophages

ABSTRACT

The cornea is one of the few tissues which actively maintain an avascular state, i.e. the absence of blood and lymphatic vessels (corneal [lymph]angiogenic privilege). Nonetheless do several diseases interfere with this privilege and cause pathologic corneal hem- and lymphangiogenesis. The ingrowths of pathologic blood and lymphatic vessels into the cornea not only reduce transparency and thereby visual acuity up to blindness, but also significantly increases the rate of graft rejections after subsequent corneal transplantation. Therefore great interest exists in new strategies to target pathologic corneal (lymph) angiogenesis to promote graft survival. This review gives an overview on the vascular anatomy of the normal ocular surface, on the molecular mechanisms contributing to the corneal (lymph)angiogenic privilege and on the cellular and molecular mechanisms occurring during pathological neo-vascularization of the cornea. In addition we summarize the current preclinical and clinical evidence for three novel treatment strategies against ocular surface diseases based on targeting pathologic (lymph) angiogenesis: (a) modulation of the immune responses after (corneal) transplantation by targeting pathologic (lymph)angiogenesis prior to and after transplantation, (b) novel concepts against metastasis and recurrence of ocular surface tumors such as malignant melanoma of the conjunctiva by anti(lymph) angiogenic therapy and (c) new ideas on how to target ocular surface inflammatory diseases such as dry eye by targeting conjunctival and corneal lymphatic vessels. Based on compelling preclinical evidence and early data from clinical trials the novel therapeutic concepts of promoting graft survival, inhibiting tumor metastasis and dampening ocular surface inflammation and dry eye disease by targeting (lymph) angiogenesis are on their way to translation into the clinic.

© 2013 Elsevier Ltd. All rights reserved.

Contents

1. Introduction	90
2. Anatomy of blood and lymphatic vessels of the cornea, limbus and conjunctiva	90
2.1. Corneal angiogenic and lymphangiogenic privilege: basic mechanisms	90
2.1.1. Corneal anatomy	91
2.1.2. Angiostatic effect of corneal cells	91
2.1.3. Antiangiogenic decoy mechanisms in the cornea	91
2.1.4. Other antiangiogenic molecules in the cornea	91
2.2. Anatomy of the limbal vascular arcade	93
2.3. Lymphatic and blood vessels in the aging cornea	94

* Corresponding author. Department of Ophthalmology, University of Cologne, Kerpener Str. 62, 50924 Cologne, Germany. Tel.: +49 (0)221 478 4300; fax: +49 (0)221 478 5094.

E-mail address: claus.cursiefen@uk-koeln.de (C. Cursiefen).

URL: <http://www.augenklinik.uk-koeln.de>

¹ Percentage of work contributed by each author in the production of the manuscript is as follows: Felix Bock: 20%: Chapter writing, manuscript coordination, proof reading, layout; Kazuichi Maruyama: 12%: chapter writing; Birgit Regenfuss: 12%: chapter writing; Deniz Hos: 12%: chapter writing; Philipp Steven: 12%: chapter writing; Ludwig Heindl: 12%: chapter writing; Claus Cursiefen: 20%: chapter writing, manuscript coordination, major proof reading.

3.	Hem- and lymphangiogenesis in corneal and ocular surface inflammation	96
3.1.	Immune cell contribution to corneal hem- and lymphangiogenesis	96
3.1.1.	Macrophages and (lymph)angiogenesis	97
3.1.2.	Macrophages and angiogenic cytokines	97
3.1.3.	Therapeutic macrophage manipulation	97
3.1.4.	Future investigations	98
3.2.	Genetic diversity in hem- and lymphangiogenesis	98
3.2.1.	Strain-dependent differences in murine corneal hemangiogenesis	98
3.2.2.	Strain-dependent differences in murine corneal lymphangiogenesis	99
4.	Novel indications for anti(lymph)angiogenic treatment strategies in corneal and ocular surface diseases	100
4.1.	Corneal grafting: promotion of corneal graft survival by targeting hem- and lymphangiogenesis	100
4.1.1.	Corneal hem- and lymphangiogenesis and transplant immunology	100
4.1.2.	Imaging of lymphatic corneal vessels: research and clinical practice	103
4.1.3.	Prevention and regression of pathologic corneal neovascularization	104
4.1.4.	Immature and mature corneal blood and lymphatic vessels	107
4.2.	Malignant tumors	108
4.2.1.	Malignant melanoma of the ciliary body with extraocular extension	111
4.2.2.	Squamous cell carcinoma of the conjunctiva	114
4.2.3.	Malignant melanoma of the conjunctiva	114
4.2.4.	Novel antilymphangiogenic treatment options for malignant tumors	115
4.3.	Inflammatory diseases at the ocular surface	116
4.3.1.	Conjunctival lymphatics	116
4.3.2.	CALT and conjunctival lymphangiogenesis: potential treatment options for autoimmune and allergic conjunctivitis	116
4.3.3.	Dry eye disease: basic science and potential therapies	117
4.4.	Other indications for targeting ocular surface (lymph)angiogenesis	117
4.4.1.	Prolymphangiogenic therapy in glaucoma	117
4.4.2.	Intraocular inflammation and sympathetic ophthalmia	117
5.	Future directions	119
	Conflict of interest	119
	Support	119
	Acknowledgments	119
	References	119

1. Introduction

The blood and lymphatic vascular systems are essential to supply organs and tissues with oxygen and nutrients, to drain redundant fluid and to facilitate the immune system to observe and defend the body against foreign organisms (Potente et al., 2011; Rovenska and Rovensky, 2011). But there are some organs and tissues which naturally are partly or completely devoid of blood and/or lymphatic vessels to maintain their unique structure and function. The cornea is one of these rare tissues which actively maintain an avascular state (corneal [lymph]angiogenic privilege). Nonetheless do several diseases interfere with this privilege and cause pathologic corneal hem- and lymphangiogenesis. The ingrowths of pathologic blood and lymphatic vessels into the cornea causes not only reduced transparency and thereby reduced visual acuity (Bachmann et al., 2013) up to blindness but also significantly increases the rate of graft rejections after subsequent transplantation. With the advent of novel anti(lymph)angiogenic drugs it became possible to test novel treatment concepts for neovascular diseases of the cornea and the ocular surface initially in animal models. Several of these novel concepts are already in the phase of translation within clinical trials or off-label use. In addition it was recognized that the cornea is, due to its normal vessel-free status and its easy accessibility, an ideal tissue to search for novel (endogenous) modulators of (lymph) angiogenesis and to study the interaction of immune cells and lymphatic vessels in (corneal) transplant immunology.

This review first gives an overview on normal ocular surface vascular anatomy and the molecular mechanisms contributing to the corneal (lymph)angiogenic privilege. This article also gives insights into the cellular and molecular mechanisms occurring during pathological neovascularization of the cornea and which efforts are

done, clinically and preclinically in terms of translation, to avoid or reduce corneal hem- and lymphangiogenesis. Finally novel treatment concepts for neovascular diseases of the cornea and the ocular surface, where our group is primarily involved, are discussed. Preclinical conceptual evidence is provided alongside with current translational efforts. Here the authors focus on:

- 1.) Modulation of immune responses after corneal transplantation by anti(lymph)angiogenic therapy as well as novel concepts for antiangiogenic therapy against mature and budding corneal neovascularization.
- 2.) Novel concepts against metastasis and recurrence of ocular surface tumors by anti(lymph)angiogenic therapy.
- 3.) New ideas on how to target ocular surface inflammatory diseases such as dry eye by targeting conjunctival and corneal lymphatic vessels as well as their imaging.

2. Anatomy of blood and lymphatic vessels of the cornea, limbus and conjunctiva

2.1. Corneal angiogenic and lymphangiogenic privilege: basic mechanisms

Normal corneal avascularity is evolutionary highly conserved, so that in all vertebrates which depend on good vision the cornea is free of blood and lymphatic vessels (Cursiefen, 2007; Cursiefen et al., 2003a, 2006c, 2002b, 2003c). The fact that the normal cornea is free of blood and lymphatic vessels and its ability to actively inhibit the ingrowths of vessels is also called the “angiogenic privilege of the cornea” (Cursiefen, 2007) in analogy to corneal

Download English Version:

<https://daneshyari.com/en/article/6202757>

Download Persian Version:

<https://daneshyari.com/article/6202757>

[Daneshyari.com](https://daneshyari.com)